144.80
-0.50
(-0.34%)
At close: January 10 at 5:35:47 PM GMT+1
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
9,607,500.00
9,835,600.00
10,173,400.00
10,981,700.00
13,444,600.00
Cost of Revenue
2,345,200.00
2,533,400.00
2,278,300.00
2,109,700.00
1,805,200.00
Gross Profit
7,262,300.00
7,302,200.00
7,895,100.00
8,872,000.00
11,639,400.00
Operating Expense
5,036,300.00
5,471,100.00
4,993,200.00
6,064,000.00
7,193,100.00
Operating Income
2,226,000.00
1,831,100.00
2,901,900.00
2,808,000.00
4,446,300.00
Net Non Operating Interest Income Expense
-188,900.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
Other Income Expense
-131,000.00
-563,900.00
847,200.00
-820,200.00
781,700.00
Pretax Income
1,906,100.00
1,296,800.00
3,591,800.00
1,745,200.00
5,047,500.00
Tax Provision
291,700.00
135,300.00
632,800.00
52,500.00
992,300.00
Earnings from Equity Interest Net of Tax
--
--
2,600.00
34,900.00
5,300.00
Net Income Common Stockholders
1,615,200.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Diluted NI Available to Com Stockholders
1,615,200.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Basic EPS
11.10
8.02
20.96
10.44
24.86
Diluted EPS
11.06
7.97
20.87
10.40
24.80
Basic Average Shares
145,300.00
144,700.00
145,300.00
149,100.00
160,900.00
Diluted Average Shares
145,975.00
145,600.00
146,000.00
149,600.00
161,300.00
Total Operating Income as Reported
--
--
--
2,840,700.00
4,550,100.00
Total Expenses
7,381,500.00
8,004,500.00
7,271,500.00
8,173,700.00
8,998,300.00
Net Income from Continuing & Discontinued Operation
1,615,200.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Normalized Income
1,723,526.82
1,663,218.40
2,340,484.80
2,346,262.00
3,375,223.60
Interest Income
72,900.00
276,500.00
89,300.00
11,000.00
42,000.00
Interest Expense
261,800.00
246,900.00
246,600.00
253,600.00
222,500.00
Net Interest Income
-188,900.00
29,600.00
-157,300.00
-242,600.00
-180,500.00
EBIT
2,167,900.00
1,543,700.00
3,838,400.00
1,998,800.00
5,270,000.00
EBITDA
2,797,200.00
2,038,500.00
4,356,800.00
2,880,100.00
5,734,800.00
Reconciled Cost of Revenue
2,088,000.00
2,279,200.00
2,125,800.00
2,503,300.00
1,812,800.00
Reconciled Depreciation
629,300.00
494,800.00
518,400.00
487,700.00
457,200.00
Net Income from Continuing Operation Net Minority Interest
1,615,200.00
1,161,100.00
3,046,900.00
1,556,100.00
4,000,600.00
Total Unusual Items Excluding Goodwill
-127,900.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Total Unusual Items
-127,900.00
-560,400.00
857,300.00
-814,600.00
778,800.00
Normalized EBITDA
2,925,100.00
2,598,900.00
3,499,500.00
3,694,700.00
4,956,000.00
Tax Rate for Calcs
0.00
0.00
0.00
0.00
0.00
Tax Effect of Unusual Items
-19,573.18
-58,281.60
150,884.80
-24,438.00
153,423.60
12/31/2020 - 9/23/1999
Upgrade to begin using 40 years of financial statements and get so much more.
Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.
UpgradeRelated Tickers
C43.DE Cosmo Pharmaceuticals N.V.
69.00
+0.73%
GIS.DE Gilead Sciences, Inc.
87.37
+1.35%
6MK.DE Merck & Co., Inc.
97.70
+0.51%
BRM.DE Bristol-Myers Squibb Company
54.92
+0.02%
SNW.DE Sanofi
95.46
-0.89%
4AB.DE AbbVie Inc.
172.44
+0.44%
GS71.DE GSK plc
16.24
-0.18%
ZEG.DE AstraZeneca PLC
131.25
+0.04%
JNJ.DE Johnson & Johnson
139.68
+1.13%
AMG.DE Amgen Inc.
256.10
-0.02%